Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. GOOG
6. CSX
7. AMD
8. IBM
9. KNX
10. LVS

Go back to Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
AGIOS PHARM (NASDAQ: AGIO) Delayed: 36.24 +0.19 (0.53%)
Previous Close $36.05    52 Week High $71.49 
Open $35.14    52 Week Low $33.50 
Day High $36.68    P/E N/A 
Day Low $35.09    EPS $-1.18 
Volume 349,767